This Resolution (RDC No. 69, 2014) establishes the procedures and practices that the manufacturer must apply in order to assure that its facilities, methods, proceedings, systems and controls used on the manufacturing of active pharmaceutical ingredients (API) are adequate in a way to guarantee its quality and allow its use on the preparation of pharmaceutical products.